Oncodesign Precision Medicine Presents Positive Phase 1 Data for RIPK2 Inhibitor OPM-101 in Healthy Volunteers
核心洞察
Oncodesign Precision Medicine (搜索) presented Phase 1 clinical trial results for OPM-101, a RIPK2 (搜索) kinase inhibitor, at UEG Week 2024, showcasing its safety profile.
The study in healthy volunteers demonstrated that OPM-101 is well-tolerated and exhibits high target engagement, supporting its potential as an oral therapy.
OPM-101 is being developed for chronic immuno-inflammatory digestive diseases, with Phase Ib/IIa trials planned to commence by the end of 2024.
Oncodesign Precision Medicine (搜索) (OPM) announced the presentation of positive Phase 1 clinical trial data for OPM-101, a first-in-class, orally available RIPK2 (搜索) inhibitor, at the United European Gastroenterology (UEG) Week congress in Vienna, Austria. The data, presented by Professor Laurent Peyrin-Biroulet, M.D., PhD, of CHRU of Nancy, highlighted the strong safety profile and high target engagement of OPM-101 in healthy volunteers.
Phase 1 Trial Results
The Phase 1 trial evaluated the safety, pharmacokinetics, and pharmacodynamics of OPM-101 in healthy volunteers. According to Professor Peyrin-Biroulet, the results provide "strong evidence that OPM has the potential to advance the treatment of Chronic Inflammatory Bowel Disease (搜索) as a daily oral therapy for people living with ulcerative colitis (搜索)."
OPM-101: A RIPK2 Kinase Inhibitor
OPM-101 is designed as a selective inhibitor of RIPK2 (搜索) kinase. OPM is advancing OPM-101 for the treatment of chronic immuno-inflammatory digestive diseases. The company plans to initiate Phase Ib/IIa trials by the end of 2024.
About Oncodesign Precision Medicine
Oncodesign Precision Medicine (搜索) (OPM) specializes in precision medicine for resistant and metastatic cancers. Their pipeline includes OPM-201, licensed to Servier for Parkinson's disease (搜索), and OPM-102, a preclinical candidate for oncology. OPM utilizes its Nanocyclix® technology platform to develop small macrocyclic kinase inhibitors.